Substituted pyrido [2,3-d] pyrimidinone compounds

Details Substituted pyrido [2,3-d] pyrimidinone compounds Substituted pyrido [2,3-d] pyrimidinone compounds

2003-05-23

2010-12-28

Wilson, James O (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S279000, C544S402000

Reexamination Certificate

active

07858631

ABSTRACT:
A variety of low molecular weight, guanidino-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases. The compounds have the structure of Formulas (IA), (IB), or (IC): where the values of the variable are defined herein.

REFERENCES:
patent: 3177218 (1965-04-01), Brown
patent: 4128643 (1978-12-01), Merkel et al.
patent: 4211867 (1980-07-01), Rasmussen
patent: 4287341 (1981-09-01), Hess et al.
patent: 4496571 (1985-01-01), Yellin et al.
patent: 4626537 (1986-12-01), Dave et al.
patent: 4732916 (1988-03-01), Satoh et al.
patent: 4748165 (1988-05-01), Jones et al.
patent: 4874864 (1989-10-01), Schnur et al.
patent: 4948891 (1990-08-01), Schnur et al.
patent: 4948901 (1990-08-01), Schnur et al.
patent: 5086057 (1992-02-01), Sasagawa
patent: 5124328 (1992-06-01), Fisher et al.
patent: 5352704 (1994-10-01), Okuyama et al.
patent: 5362902 (1994-11-01), Barnish et al.
patent: 5547966 (1996-08-01), Atwal et al.
patent: 5637439 (1997-06-01), Kaneko et al.
patent: 5731408 (1998-03-01), Hadley et al.
patent: 5750573 (1998-05-01), Bianchi et al.
patent: 5885985 (1999-03-01), Macdonald et al.
patent: 5889025 (1999-03-01), Lohray et al.
patent: 5952381 (1999-09-01), Chen et al.
patent: 5962530 (1999-10-01), Engel et al.
patent: 6020349 (2000-02-01), Ankerson et al.
patent: 6030985 (2000-02-01), Gentile et al.
patent: 6054556 (2000-04-01), Huby et al.
patent: 6060589 (2000-05-01), Stark et al.
patent: 6127343 (2000-10-01), Andersen et al.
patent: 6180603 (2001-01-01), Frey, II
patent: 6225331 (2001-05-01), Cupps et al.
patent: 6297233 (2001-10-01), Stein et al.
patent: 6313093 (2001-11-01), Frey, II
patent: 6391878 (2002-05-01), Cupps et al.
patent: 6638927 (2003-10-01), Renhowe et al.
patent: 6716840 (2004-04-01), Chu et al.
patent: 6995269 (2006-02-01), Renhowe et al.
patent: 7034033 (2006-04-01), Boyce et al.
patent: 7368453 (2008-05-01), Boyce et al.
patent: 2002/0193595 (2002-12-01), Chu et al.
patent: 2003/0195187 (2003-10-01), Boyce et al.
patent: 2003/0207814 (2003-11-01), Boyce et al.
patent: 2003/0229025 (2003-12-01), Xiao et al.
patent: 2005/0059662 (2005-03-01), Boyce et al.
patent: 2006/0030573 (2006-02-01), Boyce et al.
patent: 31 08 322 (1981-12-01), None
patent: 0343894 (1989-11-01), None
patent: WO 96/24580 (1996-08-01), None
patent: WO 97/19911 (1997-06-01), None
patent: WO 97/41119 (1997-11-01), None
patent: WO 98/07420 (1998-02-01), None
patent: WO 98/23596 (1998-06-01), None
patent: WO 99/64002 (1999-12-01), None
patent: WO 00/03973 (2000-01-01), None
patent: WO 00/03973 (2000-01-01), None
patent: WO 00/17191 (2000-03-01), None
patent: WO 00/74679 (2000-12-01), None
patent: WO 01/04103 (2001-01-01), None
patent: WO 01/10842 (2001-02-01), None
patent: WO 01/55106 (2001-08-01), None
patent: WO 01/55107 (2001-08-01), None
patent: WO 01/55109 (2001-08-01), None
patent: WO 01/70337 (2001-09-01), None
patent: WO 01/70708 (2001-09-01), None
patent: WO 02/18327 (2002-03-01), None
patent: WO 02/062776 (2002-08-01), None
patent: WO 02/081443 (2002-10-01), None
patent: WO 03/072056 (2003-09-01), None
patent: WO 03/099818 (2003-12-01), None
patent: WO 2005/051391 (2005-06-01), None
Jordan, V. C. Nature Reviews: Drug Discovery, 2, 2003, p. 205.
Dörwald, F. Zaragoza. Side Reactions in Organic Synthesis: A Guide to Successful Synthesis Design, Weinheim: WILEY-VCH Verlag GmbH & Co. KGaA, 2005, Preface.
Vippagunta, et al. Advanced Drug Delivery Reviews, 48, 2001, p. 18.
Wolff, Manfred E., Ed. Burger's Medicinal Chemistry and Drug Discovery—Fifth Edition, New York: John Wiley & Sons, 1996, vol. 1, pp. 975-976.
Wolff (Ed.),Burger's Medicinal Chemistry and Drug Discovery, 5thEdition, vol. 1: Principles and Practice, 1995, pp. 975-977, John Wiley & Sons, Inc.
Banker et al. (Eds.),Modern Pharmaceutics, 3rdEdition, Revised and Expanded, 1996, pp. 451 and 596, Marcel Dekker, Inc.
West,Solid State Chemistry and its Applications, 1988, pp. 358 and 365, John Wiley & Sons, Inc.
Goodfellow et al., “The Melanocortin System and its Role in Obesity and Cachexia,”Current Topics in Medicinal Chemistry, 2003, pp. 855-883, vol. 3, No. 8, Bentham Science Publishers Ltd.
Fisher et al., “Melanocortin-4 receptor: A novel signaling pathway involved in body weight regulation,”International Journal of Obesity, 1999, pp. 54-58, vol. 23, Suppl. 1, Stockton Press.
Supplementary European Search Report for Application No. 04811698.2 dated Oct. 7, 2008.
Asagarasu, A. et al., “Synthesis of Dipeptide-Type Human Immunodeficiency Virus (HIV) Protease Inhibitors with a Bindin Unit to GP120,”Chem. Pharm. Bull., vol. 46, No. 5, pp. 867-870, 1998, published by Pharmaceutical Society of Japan.
Dörwald, F. Zaragoza, Side Reactions in Organic Synthesis: A Guide to Successful Synthesis Design, Weinheim: WILEY-VCH Verlag GmbH & Co. KGaA, 2005, Preface.
Fehm, H. L. et al., “The Melanocortin Melanocyte-Stimulating Hormone/Adrenocorticotropin4-10Decreases Body Fat in Humans,”J. Clin. Endocrinology&Metabolism, vol. 86, No. 3, pp. 1144-1148, 2001, published by the Endocrine Society.
Fong, T. M. et al., “ART (Protein Product of Agouti-Related Transcript) as an Antagonist of MC-3 and MC-4 Receptors,”Biochemical and Biophysical Res. Comm., vol. 237, pp. 629-631, 1997, published by Academic Press.
Hadley, M. E. et al., “The Proopiomelanocortin System,”Ann. N. Y. Acad. Sci., 885:1, pp. 1-21, 1999.
Huszar, D. et al., “Targeted Disruption of the Melanocortin-4 Receptor Results in Obesity in Mice,”Cell, vol. 88, pp. 131-141, Jan. 10, 1997, published by Cell Press.
Jordan, V. C., Nature Reviews: Drug Discovery, 2, pp. 205-213, 2003.
Julia, M. et al., “Amidines and guanidines related to congocidine. III. Urea and trazene diamidines,”Bull. Soc. Chim. Fr., No. 1, pp. 376-382, 1968, published by Masson Editeur, Paris, France.
Kiefer, L.L. et al., “Mutations in the Carboxyl Terminals of the Agouti Protein Decrease Agouti Inhibition of Ligand Binding to the Melanocortin Receptors,”Biochemistry, vol. 36, pp. 2084-2090, 1997, published by American Chemical Society.
Lu, D. et al., “Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor,”Nature, vol. 371, pp. 799-802, Oct. 27, 1994.
Mountjoy, K. G. et al., “The Cloning of a Family of Genes That Encode the Melanocortin Receptors,”Science, vol. 257, pp. 1248-1251, Aug. 28, 1992.
Ollmann, M. M. et al., “Antagonism of Central Melanocortin Receptors in Vitro and in Vivo by Agouti-Related Protein,”Science, vol. 278, pp. 135-138, Oct. 3, 1997.
Rossi, M. et al., “A C-terminal fragment of Agouti-related protein increases feeding and antagonizes the effect of alpha-melanocyte stimulating hormone in vivo,”Endocrinology, vol. 139, No. 10, pp. 4428-4431, 1998, published by The Endocrine Society.
Smith, R. A. et al., “Discovery and Parallel Synthesis of a New Class of Cathepsin K Inhibitors,”Bioorganic&Medicinal Chemistry Letters, vol. 11, pp. 2951-2954, 2001, published by Elsevier Science Ltd.
Smolnik, R. et al., “Brain Potentials and Attention after Acute and Subchronic Intranasal Administration of ACTH 4-10 and Desacetyl-α-MSH in Humans,”Neuroendocrinology, vol. 70, pp. 63-72, 1999, published by S. Karger AG, Basel.
Vippagunta et al., “Crystalline solids,”Advanced Drug Delivery Reviews, 48, pp. 3-26, 2001.
Runti et al., “Fusaric Acid Derivatives and Analogues as Possible Antihypertensive Drugs,”II Farmaco—Ed. Sc., 1981, pp. 260-268, vol. 36, No. 4.

Affiliated with

Also associated with

Rating

Substituted pyrido [2,3-d] pyrimidinone compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted pyrido [2,3-d] pyrimidinone compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted pyrido [2,3-d] pyrimidinone compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4191734